(July 13, 2022) – The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research has awarded $4.2 million over five years to Mount Sinai researchers establishing a proteogenomics data analysis center (PGDAC) to advance cancer research and treatment. Proteogenomics, which studies the roles of proteins and genes within a cell or an organism, is a crucial area of exploration to deepen our understanding of cancer.
The award supports the Centre’s work to identify potential biomarkers and drug targets for cancer, new insights into cancer biology, and bioinformatics tools to enable more advanced exploration and discovery from linked data sets. to cancer.
The Centre’s principal investigators, Pei Wang, PhD, Professor of Genetic and Genomic Sciences, and Avi Ma’ayan, PhD, Professor of Pharmacological Sciences and Director of the Mount Sinai Center for Bioinformatics, will contribute their expertise in statistics/biostatistics, machine learning, data integration, systems pharmacology and modeling of proteomic data to better understand the proteogenomic complexity of tumors.
The Centers of Excellence are part of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, a national effort to advance and accelerate cancer research through the application of proteogenomics. Mount Sinai is one of 14 CPTAC centers nationwide.
The data generated and tools developed by the CPTAC centers will be made available to the public to help advance and accelerate cancer research.
About Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metropolitan area, with more than 43,000 employees working in eight hospitals, more than 400 outpatient practices, nearly 300 laboratories, a nursing school and a large school of medicine and higher education. Mount Sinai advances health for everyone, everywhere, by addressing the most complex health challenges of our time – discovering and applying new knowledge and scientific knowledge; developing safer and more effective treatments; train the next generation of medical leaders and innovators; and supporting local communities by providing high quality care to all who need it.
Through the integration of its hospitals, laboratories and schools, Mount Sinai offers comprehensive healthcare solutions from birth to geriatrics, leveraging innovative approaches such as artificial intelligence and IT while keeping patients’ medical and emotional needs at the center of all treatments. The health system includes approximately 7,300 primary and specialty care physicians; 13 joint venture day surgery centers in the five boroughs of New York, Westchester, Long Island and Florida; and over 30 affiliated community health centers. We are consistently ranked by US News & World Report’s Top Hospitals, receiving a high “Honor Roll” status, and are highly ranked: #1 in Geriatrics and Top 20 in Cardiology/Cardiac Surgery, Diabetes/Endocrinology, Gastroenterology /gastrointestinal surgery, neurology /Neurosurgery, orthopaedics, pulmonology/lung surgery, rehabilitation and urology. New York Eye and Ear Infirmary of Mount Sinai is ranked #12 in ophthalmology. US News & World Report’s “Best Hospitals for Children” ranks Mount Sinai Kravis Children’s Hospital among the best in the nation in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that has stood out on several metrics: it is consistently ranked in the top 20 by US News & World Report’s “Best Medical Schools”, aligned with a U.S. News & World Report Hospital “Honor Roll”, and among the top 20 nationwide for National Institutes of Health funding and among the top 5 nationwide for many areas of basic and clinical research. Newsweek’s “World’s Best Smart Hospitals” ranks Mount Sinai Hospital number one in New York and among the top five in the world, and Mount Sinai Morningside in the top 20 globally.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.